Coherus Oncology, Inc. (NASDAQ:CHRS) Given Average Rating of “Hold” by Analysts

Shares of Coherus Oncology, Inc. (NASDAQ:CHRS) have received an average recommendation of “Hold” from the five ratings firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $5.5125.

Several brokerages recently commented on CHRS. Wall Street Zen raised shares of Coherus Oncology from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Oppenheimer assumed coverage on shares of Coherus Oncology in a report on Thursday, January 22nd. They set an “outperform” rating and a $10.00 price target for the company.

Coherus Oncology Trading Down 19.9%

Shares of NASDAQ:CHRS opened at $1.61 on Monday. The business’s 50 day simple moving average is $1.67 and its 200 day simple moving average is $1.47. Coherus Oncology has a 1 year low of $0.71 and a 1 year high of $2.62. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.24 and a quick ratio of 1.23. The company has a market capitalization of $194.60 million, a P/E ratio of 1.21 and a beta of 0.99.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of CHRS. Panagora Asset Management Inc. acquired a new stake in shares of Coherus Oncology during the 2nd quarter worth approximately $581,000. International Assets Investment Management LLC acquired a new position in shares of Coherus Oncology during the 2nd quarter valued at $33,000. Tejara Capital Ltd boosted its stake in Coherus Oncology by 1.7% during the second quarter. Tejara Capital Ltd now owns 698,770 shares of the biotechnology company’s stock worth $511,000 after acquiring an additional 11,552 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in Coherus Oncology by 108.2% in the third quarter. BNP Paribas Financial Markets now owns 26,620 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 13,832 shares during the period. Finally, Corient Private Wealth LLC grew its holdings in Coherus Oncology by 20.0% in the second quarter. Corient Private Wealth LLC now owns 60,000 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 10,000 shares during the period. 72.82% of the stock is owned by institutional investors.

About Coherus Oncology

Coherus Oncology, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacturing and commercialization of biologic therapies for oncology support and immuno-oncology. Founded in 2010 and headquartered in Redwood City, California, Coherus specializes in biosimilar versions of established oncology agents as well as novel immunotherapy candidates.

The company’s lead marketed products include Udenyca (pegfilgrastim-cbqv) and Fulphila (pegfilgrastim-jmdb), biosimilars to Amgen’s Neulasta, which are designed to reduce the incidence of infection in patients undergoing myelosuppressive chemotherapy.